Shanghai Yizhong Pharmaceutical Co., Ltd.
SSE:688091.SS
44.59 (CNY) • At close June 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 173.533 | 360.254 | 235.957 | 4.078 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 13.332 | 23.586 | 16.97 | 0.296 | 7.134 | 5.981 | 5.52 | 0 |
| Gross Profit
| 160.2 | 336.668 | 218.987 | 3.782 | -7.134 | -5.981 | -5.52 | 0 |
| Gross Profit Ratio
| 0.923 | 0.935 | 0.928 | 0.927 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 37.192 | 22.451 | 7.926 | 13.24 | 17.893 | 178.666 | 13.508 | 14.894 |
| General & Administrative Expenses
| 15.912 | 33.504 | 3.782 | 5.378 | 4.21 | 2.825 | 2.128 | 2.794 |
| Selling & Marketing Expenses
| 81.586 | 67.761 | 89.031 | 2.318 | 0 | 0 | 0 | 0 |
| SG&A
| 97.498 | 101.117 | 92.813 | 7.696 | 4.21 | 2.825 | 2.128 | 2.794 |
| Other Expenses
| 15.958 | 17.647 | -4.161 | 3.152 | 5.534 | 139.399 | 2.008 | -0.004 |
| Operating Expenses
| 150.66 | 141.178 | 96.577 | 24.088 | 27.636 | 320.89 | 17.644 | 18.197 |
| Operating Income
| 9.541 | 195.453 | 151.587 | -20.306 | -21.841 | -315.194 | -12.589 | -10.061 |
| Operating Income Ratio
| 0.055 | 0.543 | 0.642 | -4.98 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -4.723 | -8.553 | -2.026 | 11.025 | -0.006 | -0.03 | 0 | -0.004 |
| Income Before Tax
| 4.817 | 186.9 | 149.562 | -9.281 | -21.847 | -315.224 | -12.589 | -10.065 |
| Income Before Tax Ratio
| 0.028 | 0.519 | 0.634 | -2.276 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -2.158 | 25.346 | 6.707 | -5.284 | -0.096 | -6.014 | 5.055 | -2.406 |
| Net Income
| 6.975 | 161.554 | 142.855 | -3.997 | -21.751 | -309.21 | -12.589 | -10.065 |
| Net Income Ratio
| 0.04 | 0.448 | 0.605 | -0.98 | 0 | 0 | 0 | 0 |
| EPS
| 0.03 | 0.78 | 0.9 | -0.025 | -0.14 | -1.95 | -0.12 | -0.1 |
| EPS Diluted
| 0.03 | 0.78 | 0.9 | -0.025 | -0.14 | -1.95 | -0.12 | -0.1 |
| EBITDA
| 16.682 | 195.402 | 155.992 | -1.524 | -14.684 | -309.237 | -7.064 | -14.515 |
| EBITDA Ratio
| 0.096 | 0.542 | 0.661 | -0.374 | 0 | 0 | 0 | 0 |